Company Analysis Day One Biopharmaceuticals, Inc.
1. Summary
Advantages
- The stock's return over the last year (39.79%) is higher than the sector average (5.78%).
Disadvantages
- Price (9.6 $) is higher than fair price (9.27 $)
- Dividends (0%) are below the sector average (0.5148%).
- Current debt level 0.4465% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-22.49%) is lower than the sector average (ROE=105.9%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Day One Biopharmaceuticals, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -1.3% | 7.2% | -0.2% |
| 90 days | 28.4% | 7.8% | 4% |
| 1 year | 39.8% | 5.8% | 21.1% |
DAWN vs Sector: Day One Biopharmaceuticals, Inc. has outperformed the "Healthcare" sector by 34.01% over the past year.
DAWN vs Market: Day One Biopharmaceuticals, Inc. has outperformed the market by 18.67% over the past year.
Stable price: DAWN is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: DAWN with weekly volatility of 0.7652% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (9.6 $) is higher than the fair price (9.27 $).
Price is higher than fair: The current price (9.6 $) is 3.4% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-6.09) is higher than that of the sector as a whole (-284.59).
P/E vs Market: The company's P/E (-6.09) is higher than that of the market as a whole (-77.4).
5.3. P/BV
P/BV vs Sector: The company's P/BV (2.36) is lower than that of the sector as a whole (262.42).
P/BV vs Market: The company's P/BV (2.36) is lower than that of the market as a whole (52.24).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (9.04) is lower than that of the sector as a whole (60.36).
P/S vs Market: The company's P/S indicator (9.04) is lower than that of the market as a whole (138.62).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-4.9) is lower than that of the sector as a whole (11.97).
EV/Ebitda vs Market: The company's EV/Ebitda (-4.9) is higher than that of the market as a whole (-48.38).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 26.58% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (26.58%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-22.85%).
6.4. ROE
ROE vs Sector: The company's ROE (-22.49%) is lower than that of the sector as a whole (105.9%).
ROE vs Market: The company's ROE (-22.49%) is lower than that of the market as a whole (-10.3%).
6.6. ROA
ROA vs Sector: The company's ROA (-19.92%) is lower than that of the sector as a whole (-2.97%).
ROA vs Market: The company's ROA (-19.92%) is lower than that of the market as a whole (39.94%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-191.55%) is lower than that of the sector as a whole (0.8343%).
ROIC vs Market: The company's ROIC (-191.55%) is lower than that of the market as a whole (8.78%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5148%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
